What is the management plan for a 12-year-old boy presenting with two days of periorbital edema, proteinuria, serum albumin of 2.5 g/dL, and a 1 kg weight gain?

Management of First-Episode Nephrotic Syndrome in a 12-Year-Old Boy

This 12-year-old boy presenting with periorbital edema, 2+ proteinuria, hypoalbuminemia (2.5 g/dL), and weight gain should be treated presumptively as idiopathic nephrotic syndrome with oral prednisone 60 mg/m² per day (maximum 60 mg) as a single daily dose for 6 weeks, followed by 40 mg/m² on alternate days for another 6 weeks, then tapered over 4 weeks—without requiring a kidney biopsy at this initial presentation. 1, 2

Initial Assessment and Diagnosis

This clinical presentation meets the diagnostic criteria for childhood nephrotic syndrome:

• Proteinuria: 2+ on dipstick (meets threshold)
• Hypoalbuminemia: 2.5 g/dL (≤2.5 g/dL is the established cutoff) 2
• Edema: Periorbital swelling with 1 kg weight gain
• Pyuria: 8 WBCs may indicate concurrent infection or contamination—requires culture

No kidney biopsy is needed at initial presentation in children aged 1-12 years with typical nephrotic syndrome features, as >90% have minimal change disease that responds to corticosteroids. 1, 3

Immediate Management Steps

1. Corticosteroid Therapy (First-Line Treatment)

The 2023 KDOQI commentary and 2021 consensus guidelines support either 8-week or 12-week regimens, with the 12-week protocol showing better relapse prevention 2:

Recommended regimen (16-week total course):

• Weeks 1-6: Prednisone 60 mg/m² per day (maximum 60 mg) as single morning dose daily
• Weeks 7-12: Prednisone 40 mg/m² as single morning dose on alternate days
• Weeks 13-16: Taper by 10 mg/m² per week down to 5 mg on alternate days 1

This longer initial course reduces relapse rates compared to 8-week regimens while balancing steroid toxicity concerns 4, 2.

2. Supportive Care for Edema

Fluid and sodium management:

• Restrict dietary sodium to <2 g/day (<90 mmol/day) 5
• Avoid routine IV fluids; concentrate oral intake if needed 6

Diuretic therapy (only if symptomatic edema causes discomfort or respiratory compromise):

• Start oral furosemide 1-2 mg/kg/day divided twice daily 5
• Monitor for hypovolemia signs (tachycardia, prolonged capillary refill, oliguria, abdominal pain)
• Avoid aggressive diuresis in the absence of true volume overload—periorbital edema alone does not mandate diuretics 6

Albumin infusions are NOT routinely indicated based on serum albumin levels alone. Reserve for clinical hypovolemia (oliguria, acute kidney injury, hypotension) or failure to thrive 6.

3. Infection Prophylaxis and Screening

• Urine culture: Mandatory given pyuria (8 WBCs)—treat if positive before starting high-dose steroids
• Consider penicillin V prophylaxis for spontaneous bacterial peritonitis if significant ascites develops (not needed for mild periorbital edema) 7
• Pneumococcal and varicella vaccination status: Update before or after steroid course (live vaccines contraindicated during treatment)

4. Monitoring During Initial Treatment

Weekly for first 4-6 weeks:

• Daily home urine dipstick (teach family to check first morning urine)
• Weight monitoring
• Blood pressure

Laboratory monitoring:

• Assess for remission at 2 weeks, then weekly: First morning urine dipstick
• Remission definition: Trace or negative proteinuria for 3 consecutive days 1
• If no remission by 4 weeks: Continue steroids to 6-8 weeks before declaring steroid resistance 1

Expected response:

• 80-90% achieve remission within 4 weeks
• If steroid-resistant (no remission after 8 weeks): Proceed to kidney biopsy and genetic testing 1, 3

Common Pitfalls to Avoid

1. Underdosing steroids: Always calculate by body surface area (BSA), not just weight—maximum 60 mg daily dose applies 1

2. Premature biopsy: Do not biopsy at presentation unless age <1 year, age >12 years, gross hematuria, hypertension, or reduced kidney function 1, 3

3. Aggressive albumin administration: Albumin infusions based solely on lab values (rather than clinical hypovolemia) increase thrombosis risk without improving outcomes 6

4. Stopping steroids too early: The full 12-16 week course reduces relapse rates—do not abbreviate even if remission occurs quickly 2

5. Missing concurrent infection: Always culture urine when pyuria present; infections can trigger relapse and complicate steroid therapy 7

Subsequent Management Based on Disease Course

If infrequent relapses occur (<2 relapses in 6 months):

• Treat each relapse with prednisone 60 mg/m² daily until remission (3 consecutive days trace/negative), then 40 mg/m² alternate days for 4 weeks 1

If frequent relapses (≥2 in 6 months) or steroid-dependent pattern emerges:

• Consider steroid-sparing agents: levamisole (first-line if available), cyclophosphamide, rituximab, or calcineurin inhibitors 1, 3
• Refer to pediatric nephrology for co-management

If steroid-resistant (no remission by 8 weeks):

• Kidney biopsy mandatory
• Genetic testing
• Start calcineurin inhibitor (tacrolimus or cyclosporine) 1, 3

Long-Term Outlook

Approximately 80% of children with steroid-sensitive nephrotic syndrome will experience at least one relapse, and 50% develop frequently relapsing or steroid-dependent disease 4. However, long-term kidney outcomes remain excellent for steroid-sensitive disease, with most achieving sustained remission by adolescence or early adulthood 8.